AstraZeneca at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
AstraZeneca takes part in 6 sessions at ESMO 2026 in Madrid, and exhibits at Booth 8066. Its program centres on lung and breast cancer, with a strong focus on caring for patients treated with antibody-drug conjugates, including the role of nurses. It also covers new biomarkers and combinations in lung cancer, first-line breast cancer care across subtypes and gastroesophageal cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
AstraZeneca Cambridge, United Kingdom | |
Global pharmaceutical company with a large oncology portfolio including osimertinib, durvalumab, olaparib and trastuzumab deruxtecan. | Booth Exhibiting at Booth 8066 Talk Fri Oct 23 13:30 Satellite Fri Oct 23 18:15–19:45 AstraZeneca - Advancing excellence in lung cancer: New biomarkers, novel combinations, and changing standards of care Lung & thoracic cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:00–14:30 Satellite Sun Oct 25 10:15–11:45 AstraZeneca - On the frontlines: Optimizing ADC patient care in lung cancer Lung & thoracic cancersNursing & supportive care Satellite Sun Oct 25 12:00–13:00 Daiichi Sankyo | AstraZeneca - Piecing together the ADC patient journey: The vital role of nurses in advanced breast cancer care Breast cancerNursing & supportive care Satellite Mon Oct 26 13:00–14:30 AstraZeneca - Advancing clinical practice and patient care in gastroesophageal cancer Gastrointestinal cancers |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction